Gilead SciencesFRA:GIS +4.15%69 Days Inventory is 115.73 as of Mar. 2026, which is 15% above its 10-year median of 100.26. GuruFocus rates FRA:GIS with a GF Score™ of 69/100 and a GF Value™ of €82.35 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 919 Drug Manufacturers companies, Gilead Sciences ranks better than 76.06% on this metric.
The historical rank and industry rank for Gilead Sciences's Days Inventory or its related term are showing as below:
FRA:GIS'
s Days Inventory Range Over the Past 10 Years
Min: 60.73 Med: 100.26 Max: 151.7
Current: 107.7
During the past 13 years, Gilead Sciences's highest Days Inventory was 151.70. The lowest was 60.73. And the median was 100.26.
FRA:GIS's Days Inventory is ranked better than 76.06% of 919
companies
in the Drug Manufacturers industry
Industry Median: 164.48
vs FRA:GIS: 107.70
Gilead Sciences's Days Inventory
increased
from Mar. 2025 (104.42) to Mar. 2026 (115.73).
It might indicate that Gilead Sciences's sales slowed down.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Gilead Sciences's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.79.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Gilead Sciences's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.26.
Gilead Sciences (FRA:GIS) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Gilead Sciences's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Gilead Sciences's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Gilead Sciences Days Inventory Related Terms
Gilead Sciences Days Inventory Historical Data
* Premium members only.
The historical data trend for Gilead Sciences's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:GIS vs PFE, AMGN, BMY: Days Inventory Comparison
For the Drug Manufacturers - General subindustry, Gilead Sciences's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gilead Sciences Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's Days Inventory distribution charts can be found below:
* The bar in red indicates where Gilead Sciences's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gilead Sciences (FRA:GIS) has a Days Inventory of 115.73 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Gilead Sciences and its competitors. This is 15% above median its historical median of 100.26. Over the past decade, Gilead Sciences' Days Inventory has ranged from 60.73 to 151.70. According to the industry distribution chart, Gilead Sciences ranks #220 out of 919 companies in the Drug Manufacturers industry, placing it in the top 23.9%.
Is Gilead Sciences' Days Inventory too high?
Gilead Sciences' current Days Inventory of 115.73 is 15% above median its 10-year median of 100.26. Over the past 10 years, this metric has ranged from a low of 60.73 to a high of 151.70. The Drug Manufacturers industry median Days Inventory is 164.48. Gilead Sciences' value of 115.73 is 29.6% below this industry median. Based on the distribution chart, Gilead Sciences ranks #220 out of 919 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Gilead Sciences has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Gilead Sciences' Days Inventory compare to PFE and AMGN?
According to the Drug Manufacturers industry distribution chart, Gilead Sciences ranks #220 out of 919 companies for Days Inventory. This places Gilead Sciences in the top 24% of its industry — outperforming the majority of peers. The industry median Days Inventory is 164.48. Gilead Sciences' value of 115.73 is 29.6% below this benchmark. Historically, Gilead Sciences' own Days Inventory has ranged from 60.73 to 151.70 over the past decade. While the company's 10-year median is 100.26 vs. the industry median of 164.48, Gilead Sciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 164.48, based on 919 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gilead Sciences's current Days Inventory of 115.73 is 29.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Gilead Sciences and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 164.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gilead Sciences's current Days Inventory is 115.73, which is 15% above median its own 10-year median of 100.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gilead Sciences stock overvalued right now?
Based on GuruFocus' analysis, Gilead Sciences (FRA:GIS) is currently considered Significantly Overvalued. The stock's GF Value™ is €82.35, compared to a current price of €117.50 — trading 42.7% above its estimated fair value. The current Days Inventory is 115.73, which is 15% above median its 10-year median of 100.26 and 29.6% below the Drug Manufacturers industry median of 164.48. Gilead Sciences' overall GF Score™ is 69/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Gilead Sciences (FRA:GIS), the current Days Inventory is 115.73 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gilead Sciences (FRA:GIS) Overvalued in 2026?
Based on GuruFocus' analysis, Gilead Sciences stock appears to be overvalued.
The current stock price of €117.50 is trading 42.7% above its estimated GF Value™ of €82.35.
GuruFocus considers Gilead Sciences to be Significantly Overvalued.
Key valuation signals for FRA:GIS:
Days Inventory: 115.73 (15% above median its 10-year median of 100.26)
GF Value™: €82.35 vs. price of €117.50 (42.7% above fair value)
Industry Position: 29.6% below the Drug Manufacturers median (#220 of 919)
No single metric tells the full story. See the FRA:GIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
69GF Score
Get the complete analysis for FRA:GIS
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:GIS has been successfully added to your 
